These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10559570)

  • 1. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation.
    Wahlund LO; Basun H; Almkvist O; Julin P; Axelman K; Shigeta M; Jelic V; Nordberg A; Lannfelt L
    Dement Geriatr Cogn Disord; 1999; 10(6):526-33. PubMed ID: 10559570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment.
    Almkvist O; Axelman K; Basun H; Jensen M; Viitanen M; Wahlund LO; Lannfelt L
    Acta Neurol Scand Suppl; 2003; 179():77-82. PubMed ID: 12603253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer amyloid protein mutation.
    Julin P; Almkvist O; Basun H; Lannfelt L; Svensson L; Winblad B; Wahlund LO
    Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):49-53. PubMed ID: 9539411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.
    Basun H; Bogdanovic N; Ingelsson M; Almkvist O; Näslund J; Axelman K; Bird TD; Nochlin D; Schellenberg GD; Wahlund LO; Lannfelt L
    Arch Neurol; 2008 Apr; 65(4):499-505. PubMed ID: 18413473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations.
    Lee GJ; Lu PH; Medina LD; Rodriguez-Agudelo Y; Melchor S; Coppola G; Braskie MN; Hua X; Apostolova LG; Leow AD; Thompson PM; Ringman JM
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):154-62. PubMed ID: 23085935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years.
    Mondadori CR; Buchmann A; Mustovic H; Schmidt CF; Boesiger P; Nitsch RM; Hock C; Streffer J; Henke K
    Brain; 2006 Nov; 129(Pt 11):2908-22. PubMed ID: 17012294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease.
    Almkvist O; Rodriguez-Vieitez E; Thordardottir S; Amberla K; Axelman K; Basun H; Kinhult-Ståhlbom A; Lilius L; Remes A; Wahlund LO; Viitanen M; Lannfelt L; Graff C
    J Int Neuropsychol Soc; 2017 Mar; 23(3):195-203. PubMed ID: 28079014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.
    Hausner L; Tschäpe JA; Schmitt HP; Hentschel F; Hartmann T; Frölich L
    Alzheimers Dement; 2014 Mar; 10(2):e27-39. PubMed ID: 23850332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.
    Acosta-Baena N; Sepulveda-Falla D; Lopera-Gómez CM; Jaramillo-Elorza MC; Moreno S; Aguirre-Acevedo DC; Saldarriaga A; Lopera F
    Lancet Neurol; 2011 Mar; 10(3):213-20. PubMed ID: 21296022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes.
    Almkvist O; Rodriguez-Vieitez E; Thordardottir S; Nordberg A; Viitanen M; Lannfelt L; Graff C
    Neurobiol Aging; 2019 Oct; 82():40-47. PubMed ID: 31386938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.
    Schöll M; Almkvist O; Bogdanovic N; Wall A; Långström B; Viitanen M; Nordberg A
    J Alzheimers Dis; 2011; 24(3):495-506. PubMed ID: 21297272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.
    Lee S; Viqar F; Zimmerman ME; Narkhede A; Tosto G; Benzinger TL; Marcus DS; Fagan AM; Goate A; Fox NC; Cairns NJ; Holtzman DM; Buckles V; Ghetti B; McDade E; Martins RN; Saykin AJ; Masters CL; Ringman JM; Ryan NS; Förster S; Laske C; Schofield PR; Sperling RA; Salloway S; Correia S; Jack C; Weiner M; Bateman RJ; Morris JC; Mayeux R; Brickman AM;
    Ann Neurol; 2016 Jun; 79(6):929-39. PubMed ID: 27016429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.
    Thordardottir S; Rodriguez-Vieitez E; Almkvist O; Ferreira D; Saint-Aubert L; Kinhult-Ståhlbom A; Thonberg H; Schöll M; Westman E; Wall A; Eriksdotter M; Zetterberg H; Blennow K; Nordberg A; Graff C
    Alzheimers Res Ther; 2018 May; 10(1):45. PubMed ID: 29747683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation.
    Almkvist O; Axelman K; Basun H; Wahlund LO; Lannfelt L
    J Neural Transm Suppl; 2002; (62):117-25. PubMed ID: 12456057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.
    Braskie MN; Medina LD; Rodriguez-Agudelo Y; Geschwind DH; Macias-Islas MA; Thompson PM; Cummings JL; Bookheimer SY; Ringman JM
    Hum Brain Mapp; 2013 Dec; 34(12):3308-19. PubMed ID: 22806961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation.
    Mustafa A; Lannfelt L; Lilius L; Islam A; Winblad B; Adem A
    Dement Geriatr Cogn Disord; 1999; 10(6):446-51. PubMed ID: 10559558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family.
    Lannfelt L; Bogdanovic N; Appelgren H; Axelman K; Lilius L; Hansson G; Schenk D; Hardy J; Winblad B
    Neurosci Lett; 1994 Feb; 168(1-2):254-6. PubMed ID: 8028788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.